Bortezomib neurotoxicity treatment of multiple myeloma: single center experience and literature review
| Autor: | N. V. Stepanova, E. R. Machulaitene, G. N. Salogub, E. V. Melnikova |
|---|---|
| Jazyk: | ruština |
| Rok vydání: | 2022 |
| Předmět: | |
| Zdroj: | Онкогематология, Vol 0, Iss 1, Pp 21-28 (2022) |
| Druh dokumentu: | article |
| ISSN: | 1818-8346 2413-4023 |
| DOI: | 10.17650/1818-8346-2009-0-1-21-28 |
| Popis: | Peripheral neuropathy is one of the most common complications of Bortezomib treatment. In this article you can find a brief literature review and single center experience: we estimated the prevalence of neuropathy development and it’s characteristics in a group of 33 patients. Peripheral neuropathy was found in 16 (48.5%) patients. In this group initial manifestations of neurotoxicity (grade I and II) were found in 8 (50%) patients. Advanced neuropathy (grade III and IV) was found in 6 (37.5%) and 2 (12.5%) patients respectively. In the majority of patients neuropathy was reversible if Bortezomibe dose was modified and symptomatic treatment was administered at the proper time. |
| Databáze: | Directory of Open Access Journals |
| Externí odkaz: |
|